Review Article
Drug Therapy
Direct Thrombin Inhibitors
N Engl J Med 2005; 353:1028-1040September 8, 2005
- Article
Animation
Mechanism of Action of Direct Thrombin Inhibitors as Compared with Heparin.
Direct thrombin inhibitors (DTIs) are a new class of anticoagulants that bind directly to thrombin and block its interaction with its substrates. Some DTIs — such as recombinant hirudins, bivalirudin, and ximelagatran, either alone or in combination with melagatran — have undergone extensive evaluation in phase 3 trials for the prevention and treatment of arterial and venous thrombosis. The evidence concerning the clinical applicability of other DTIs, such as argatroban and dabigatran, is limited to phase 2 studies. Four parenteral DTIs have been approved by the Food and Drug Administration (FDA) in North America: hirudin and argatroban for the treatment of heparin-induced thrombocytopenia, bivalirudin as an alternative to heparin in percutaneous coronary intervention, and desirudin as prophylaxis against venous thromboembolism in hip replacement. This review discusses FDA-approved DTIs as well as those under evaluation in phase 2 or 3 clinical trials.
Mechanisms of Action
Coagulation Cascade and Generation of Thrombin
After injury to a vessel wall, tissue factor is exposed on the surface of the damaged endothelium. The interaction of tissue factor with plasma factor VII activates the coagulation cascade, producing thrombin by stepwise activation of a series of proenzymes (Figure 1Figure 1
Thrombin Generation.). Thrombin is central in the clotting process: it converts soluble fibrinogen to fibrin; activates factors V, VIII, and XI, which generates more thrombin; and stimulates platelets. Furthermore, by activating factor XIII, thrombin favors the formation of cross-linked bonds among the fibrin molecules, stabilizing the clot. The coagulation cascade is regulated by natural anticoagulants, such as tissue factor pathway inhibitor, the protein C and protein S system, and antithrombin, all of which help to restrict the formation of the hemostatic plug to the site of injury.Differences from Heparins
Thrombin-inhibiting drugs can block the action of thrombin by binding to three domains: the active site or catalytic site and two exosites (Figure 2Figure 2
Mechanism of Action of Direct Thrombin Inhibitors as Compared with Heparin.). Located next to the active site, exosite 1 acts as a dock for substrates such as fibrin, thereby orienting the appropriate peptide bonds in the active site. Exosite 2 serves as the heparin-binding domain.1 Thrombin is inhibited indirectly by low-molecular-weight heparins, because these drugs strongly catalyze the function of antithrombin. A heparin–thrombin–antithrombin complex is formed in which heparin binds simultaneously to exosite 2 in thrombin and to antithrombin. Furthermore, heparin can act as a bridge between thrombin and fibrin by binding both to fibrin and exosite 2 (Figure 2). Because both thrombin exosites are occupied within this fibrin–heparin–thrombin complex, the enzymatic activity of thrombin is relatively protected from inactivation by the heparin–antithrombin complex.2-4 Thus, heparins have a reduced capacity for the inhibition of fibrin-bound thrombin, which appears to be detrimental, because active thrombin further triggers thrombus growth.Since DTIs act independently of antithrombin, they can inhibit thrombin bound to fibrin or fibrin degradation products.3-5 Bivalent DTIs block thrombin at both the active site and exosite 1, whereas univalent DTIs bind only to the active site. The group of bivalent DTIs includes hirudin and bivalirudin, whereas argatroban, melagatran (and its oral precursor, ximelagatran), and dabigatran are univalent DTIs. Native hirudin and recombinant hirudins (lepirudin and desirudin) form an irreversible 1:1 stoichiometric complex with thrombin.6 In a similar way, bivalirudin, a synthetic hirudin, binds to the active site and exosite 1,7 but once bound, it is cleaved by thrombin, thereby restoring the active-site functions of thrombin.8 Therefore, in contrast to the hirudins, bivalirudin produces only a transient inhibition of thrombin.
By interacting only with the active site, univalent DTIs inactivate fibrin-bound thrombin.9,10 Argatroban and melagatran (like bivalirudin) dissociate from thrombin, leaving a small amount of free, enzymatically active thrombin available for hemostatic interactions.11,12
By reducing the thrombin-mediated activation of platelets, DTIs also have an antiplatelet effect.13,14 Since DTIs do not bind to plasma proteins, these agents should produce a more predictable response than does unfractionated heparin and should be more effective than low-molecular-weight heparins because they inhibit fibrin-bound thrombin.
Pharmacokinetics and Pharmacodynamics
The routes of administration, plasma half-lives, and main sites of clearance of the various DTIs are listed in Table 1Table 1
Main Properties and Pharmacokinetic Characteristics of Direct Thrombin Inhibitors.. DTIs with a predominant renal clearance such as hirudin, melagatran, and dabigatran are likely to accumulate in patients with impaired renal function.12,15 Although excessive anticoagulation with hirudin in patients with renal insufficiency can be managed with high-volume hemofiltration with hirudin-permeable hemodialysis membranes,15 the available data remain scarce. Studies in animals suggest that excessive plasma concentrations of melagatran can be managed by either hemodialysis or the administration of activated prothrombin complex concentrates.12 Since patients with severe renal impairment have been excluded from the clinical trials, the safety of DTIs that are predominantly cleared by the kidneys remains to be established.Bivalirudin is only partially excreted by the kidneys, as hepatic metabolism and proteolysis at other sites also contribute to its metabolism.16 However, the half-life of bivalirudin is prolonged with severe renal impairment, and dose adjustments are needed.17
Argatroban is predominantly cleared by hepatic metabolism and requires dose adjustments in patients with hepatic dysfunction.18 The use of aspirin does not appear to influence the plasma concentrations of DTIs.19,20
Studies in Arterial Thrombosis
Acute Coronary Syndromes with or without Percutaneous Coronary Intervention
Patients with acute coronary syndromes (acute myocardial infarction, either with or without ST-segment elevation, and unstable angina) remain at risk for recurrent myocardial ischemia, despite treatment with aspirin, clopidogrel, and heparin.21,22 The role of DTIs in the management of acute coronary syndromes was reviewed by the Direct Thrombin Inhibitor Trialists' Collaborative Group in a meta-analysis of data on individual patients.23 Eleven randomized trials were pooled, providing a total of 35,970 patients who were assigned to receive either DTIs or unfractionated heparin from 24 hours up to 7 days and then were followed for at least 30 days. As compared with heparin, DTIs reduced the incidence of the composite outcome of death and myocardial infarction both at the end of treatment and at 30 days (Table 2Table 2
Clinical Studies Comparing Direct Thrombin Inhibitors with Control Therapy in Patients with Coronary Syndromes (with or without Percutaneous Coronary Intervention) or Atrial Fibrillation.). The difference in risk appeared to be due mainly to a significant reduction in myocardial infarction, without a significant effect on death. The analysis by agent revealed that benefits were similar for hirudin and bivalirudin, whereas a nonsignificant, small increase in the risk of death or myocardial infarction was observed with univalent DTIs. Serious bleeding occurred less frequently among patients receiving DTIs than among those receiving heparin, but there was substantial heterogeneity for this outcome. Serious bleeding occurred more frequently with hirudin than with heparin but less often with bivalirudin and univalent inhibitors. The data on univalent DTIs should be interpreted with caution owing to the rather small number of events and the fact that these results are derived from dose-finding studies, with all dosage groups combined.In 2001, the data from another randomized clinical trial in acute coronary syndromes became available.24 In this study, patients with myocardial infarction characterized by ST-segment elevation were randomly assigned to receive either bivalirudin or unfractionated heparin combined with streptokinase.24 No difference was observed in the primary outcome of 30-day mortality between the two treatment groups, although a benefit of bivalirudin was observed for the secondary outcome of reinfarction within 96 hours. In contrast to the results of the meta-analysis, rates of serious bleeding were not lower with bivalirudin.
Some aspects regarding the role of DTIs in acute coronary syndromes require comment. In the trials reviewed in the meta-analysis23 and in the Hirulog and Early Reperfusion or Occlusion 2 (HERO-2) study,24 DTIs have been compared with unfractionated heparin. However, several analyses have suggested that low-molecular-weight heparin may be superior to unfractionated heparin in patients with unstable angina and myocardial infarction.29-31 Moreover, aggressive antiplatelet therapy has become the standard treatment in acute coronary syndromes, and the role of DTIs has not been established in the setting of the combined use of aspirin and clopidogrel, as well as glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitors.
Therefore, hirudin is an unattractive alternative for the treatment of patients with acute coronary syndromes, given the lack of a clear efficacy benefit, the observed increase in bleeding, and the higher cost as compared with unfractionated heparin. In a similar manner, bivalirudin does not appear to be more efficacious or safer than unfractionated heparin and cannot be recommended in this setting.
Percutaneous Coronary Intervention
The meta-analysis mentioned above23 suggested that the prespecified subgroup of patients undergoing percutaneous coronary intervention had no significant efficacy benefit, but the incidence of serious bleeding was less with hirudin and bivalirudin than with unfractionated heparin.
Bivalirudin was compared with heparin during coronary angioplasty for unstable or postinfarction angina. Initial results suggested that there was a benefit,32 a finding that was supported in a longer-term follow-up using an intention-to-treat analysis.33 The combined outcome of death, myocardial infarction, and revascularization at 7 and 90 days occurred less frequently with bivalirudin, mainly owing to an effect on the need for revascularization. At 90 days, serious bleeding was significantly reduced in the bivalirudin group (3.7 percent vs. 9.3 percent).33
The meta-analysis23 pooled data from trials that were conducted before the introduction of newer therapies such as intracoronary stenting and the use of GPIIb/IIIa inhibitors. In the Randomized Evaluation in Percutaneous Coronary Intervention Linking Angiomax to Reduced Clinical Events 2 (REPLACE-2) study, patients undergoing urgent or elective percutaneous coronary intervention were randomly assigned to receive unfractionated heparin plus GPIIb/IIIa inhibitors or to receive bivalirudin to which GPIIb/IIIa inhibitors were added only if complications occurred during the procedure.25 Aspirin was prescribed to all patients, and the use of clopidogrel was encouraged. The composite efficacy and safety outcome of death, myocardial infarction, urgent repeat revascularization, and serious bleeding was not significantly different between the two groups. However, the use of bivalirudin was associated with a lower rate of serious bleeding. GPIIb/IIIa inhibitors were used in only 7.2 percent of the bivalirudin recipients, which may have contributed to the lower costs associated with this approach.34 The composite outcome remained not significantly different at six months35 and was not affected by concomitant clopidogrel treatment.36 A subanalysis of this trial confirmed the similar efficacy and the lower incidence of bleeding for bivalirudin, regardless of renal function.37
In summary, bivalirudin appears to be safer than heparin in patients undergoing percutaneous coronary intervention, provided that GPIIb/IIIa inhibitors are administered if complications occur during the procedure.
Long-Term Treatment of Acute Coronary Syndromes
In patients with acute coronary syndromes, long-term treatment with aspirin leads to a reduction in the relative risk of recurrent ischemic events of approximately 23 percent.21,22 The addition of vitamin K antagonists further reduces cardiovascular complications, but at the expense of more bleeding.21,22 Long-term treatment with low-molecular-weight heparin does not offer an additional benefit over aspirin alone.21,22,38 The role of DTIs for long-term secondary prophylaxis in patients also receiving aspirin was investigated in the Efficacy and Safety of the Oral Direct Thrombin Inhibitor Ximelagatran in Patients with Recent Myocardial Damage (ESTEEM) trial.26 Ximelagatran in four oral doses was compared with placebo in patients with myocardial infarction. Ximelagatran significantly reduced the incidence of the combined outcome of all-cause mortality, nonfatal myocardial infarction, and severe recurrent ischemia during the six-month treatment period as compared with placebo, without a dose–response effect. The use of ximelagatran was not associated with a rate of serious bleeding higher than that of aspirin alone, but the total risk of bleeding was higher and dose-related. Elevation of alanine aminotransferase of more than three times the upper limit of normal occurred in 11 percent of the patients treated with ximelagatran and in 2 percent of those receiving placebo.
In summary, the investigation of the role of ximelagatran in the long-term treatment of acute coronary syndromes is limited to one phase 2 trial that was promising with respect to efficacy but identified possible hepatic toxicity as an important concern. Thus, at present, ximelagatran should not be considered for long-term treatment after acute coronary syndromes.
Atrial Fibrillation
The most serious clinical complication of atrial fibrillation is ischemic stroke.39 Although aspirin is the treatment of choice for low-risk patients, vitamin K antagonists are preferred for high-risk patients since there is a 36 percent reduction in the relative risk of stroke as compared with aspirin.39
Ximelagatran was compared with dose-adjusted warfarin for the prevention of all strokes and systemic embolism in patients with nonvalvular atrial fibrillation and at least one additional risk factor in the trials called Stroke Prevention Using an Oral Thrombin Inhibitor in Atrial Fibrillation III (SPORTIF III) and SPORTIF V.27,28 These two studies had an identical design, except that the SPORTIF III trial was open-label, whereas the SPORTIF V trial was double-blinded. Ximelagatran was observed to be as effective as warfarin with respect to the primary efficacy outcome of stroke or systemic embolism. Furthermore, ximelagatran conferred a significantly lower risk of serious bleeding in the pooled analysis. Ximelagatran was associated with a significant increase in the proportion of patients with alanine aminotransferase levels at least three times the upper limit of normal as compared with warfarin (6.1 percent vs. 0.8 percent).
On the basis of the SPORTIF trials, ximelagatran might be a convenient alternative for vitamin K antagonists in patients who have atrial fibrillation plus at least one additional risk factor. However, the safety of this management strategy remains to be determined.
Prevention of Venous Thromboembolism
Despite prophylaxis, the rate of symptomatic venous thromboembolism in patients undergoing serious orthopedic surgery remains as high as 1.5 to 10 percent in the three months following surgery.42 Desirudin, melagatran, and ximelagatran have been studied in phase 3 trials in patients undergoing hip or knee surgery (Table 3Table 3
Clinical Studies Comparing Direct Thrombin Inhibitors with Control Therapy for Prophylaxis and Treatment of Venous Thromboembolism.). Recently, a pilot study investigated the role of the combination of melagatran and ximelagatran in elective abdominal surgery.53 Ximelagatran
Oral ximelagatran has been investigated either alone or in combination with subcutaneous melagatran for the prevention of venous thromboembolism after orthopedic surgery. In a double-blind, randomized trial among patients undergoing total hip replacement, the efficacy and safety of initiating oral ximelagatran after surgery, as compared with enoxaparin, were evaluated.43 The rates of both overall venous thromboembolism and proximal deep venous thrombosis (with or without pulmonary embolism) were significantly higher in patients receiving ximelagatran than they were among those treated with enoxaparin; the incidence of episodes of serious bleeding was similar.
Warfarin (with the use of a target international normalized ratio of 2.5) has been the control treatment in two phase 3 trials among patients undergoing total knee replacement.44,45 Both treatments were started postoperatively. In the first study, the incidence of overall venous thromboembolism and proximal deep venous thrombosis (with or without symptomatic pulmonary embolism) was not significantly lower in patients receiving ximelagatran; the incidence of serious bleeding was similar in the two groups.44 In the second trial, two doses of ximelagatran were compared with warfarin in order to demonstrate superiority of the higher ximelagatran dose.45 A dose of 36 mg of ximelagatran reduced the rate of overall deep venous thrombosis as compared with both 24 mg of ximelagatran and warfarin. Serious bleeding occurred with a similar frequency in all groups. Elevations of alanine aminotransferase that were more than three times the upper limit of normal were observed less frequently with both doses of ximelagatran than with warfarin at the end of treatment, though the levels had normalized in the warfarin group four to six weeks later, whereas persistent increases in levels of alanine aminotransferase were observed in some patients in the ximelagatran groups (0.6 percent and 0.1 percent in the high- and low-dose groups, respectively).
Melagatran–Ximelagatran
The efficacy of the use of subcutaneous melagatran followed by oral ximelagatran was tested in two phase 3 trials among patients undergoing total hip or total knee replacement.46,48 In the Melagatran for Thrombin Inhibition in Orthopedic Surgery III (METHRO III) study, postoperative initiation of melagatran followed by ximelagatran was compared with preoperative initiation of enoxaparin.46 Both groups in the study were associated with similar rates of venous thromboembolism and of serious bleeding. In the Expanded Prophylaxis Evaluation Surgery Study (EXPRESS), the administration of melagatran before surgery followed by ximelagatran was compared with preoperative administration of enoxaparin.48 The rates of venous thromboembolism were significantly lower with the melagatran–ximelagatran regimen, but both serious and minor bleeding were observed more frequently.
Desirudin
Two phase 3 trials have evaluated preoperative administration of desirudin among patients undergoing hip replacement.49,50 In one study, desirudin was compared with preoperative administration of enoxaparin.49 The incidence of overall and proximal deep venous thrombosis was lower in patients treated with desirudin, with a similar risk of serious bleeding in the two groups. In the other study, preoperative administration of desirudin was compared with preoperative administration of unfractionated heparin.50 Desirudin reduced the incidence of overall and proximal deep venous thrombosis. Serious bleeding episodes were similar in the two groups.
Dabigatran
The Boehringer Ingelheim Study in Thrombosis II (BISTRO II) trial, a phase 2 study, compared oral dabigatran with enoxaparin in the prevention of venous thromboembolism after orthopedic surgery.47 Dabigatran was started 1 to 4 hours after surgery, whereas enoxaparin was initiated 12 hours before surgery. The highest doses of dabigatran were associated with a significantly lower incidence of venous thromboembolism than was enoxaparin. However, the risk of serious bleeding with dabigatran increased in a dose-dependent manner.
Perioperative Timing
The timing for the initiation of thromboprophylaxis relative to surgery might be more important with the administration of DTIs than with low-molecular-weight heparin, although, to our knowledge, a direct comparison has not been performed.42 The administration of ximelagatran alone or combined with subcutaneous melagatran postoperatively appears to be less effective than low-molecular-weight heparin but more effective than warfarin, with similar bleeding risks. In the administration of preoperative prophylaxis, both desirudin and the combination of melagatran and ximelagatran were observed to be more effective than either unfractionated or low-molecular-weight heparin.48-50 However, the reduction in thromboembolic events with either ximelagatran or melagatran was offset by more bleeding episodes.
Current data, taken together, suggest no important advantages to using most DTIs as compared with the routine use of low-molecular-weight heparin for prophylaxis of venous thromboembolism. The one exception appears to be desirudin, which can be recommended for prophylaxis among patients undergoing hip replacement.
Treatment of Established Venous Thromboembolism
Initial Treatment
Phase 2 studies with recombinant hirudin and melagatran have consistently suggested a similar efficacy and safety of DTIs as compared with standard treatment with low-molecular-weight heparin plus vitamin K antagonists for the initial treatment of venous thromboembolism.54,55 In the phase 3 Thrombin Inhibitor in Venous Thromboembolism (THRIVE) study, patients with deep venous thrombosis were randomly assigned to receive either six months of oral ximelagatran or initial treatment with subcutaneous enoxaparin combined with warfarin.51 Ximelagatran was as effective as the combination therapy, and rates of bleeding complications were similar. However, alanine aminotransferase levels increased to more than three times the upper limit of normal in 9.6 percent of the patients receiving ximelagatran and in 2.0 percent of those treated with the combination of enoxaparin and warfarin. Thus, oral ximelagatran was as effective for the treatment of venous thromboembolism without the need for monitoring, but there was concern about safety, given increases in hepatic enzymes.
Long-Term Secondary Prophylaxis
After six months of treatment with vitamin K antagonists, patients with venous thromboembolism have a 5 to 7 percent risk of recurrence in the first year after discontinuation.56 Therefore, long-term treatment has been recommended for patients at high risk for recurrence. Extended prophylaxis with ximelagatran was compared with placebo for 18 months in patients with thromboembolism who had been treated with vitamin K antagonists for at least 6 months.52 Ximelagatran significantly reduced the rate of recurrent venous thromboembolism without a significant increase in the incidence of either serious or minor bleeding. However, ximelagatran was associated with a significantly increased rate of elevated alanine aminotransferase levels (6.4 percent vs. 1.2 percent). Thus, there is concern about hepatic toxicity with long-term use of ximelagatran.
Heparin-Induced Thrombocytopenia
Heparin-induced thrombocytopenia is an adverse drug reaction mediated by the immune system, with clinical manifestations initiated by antibodies directed against platelet factor 4, which becomes an antigenic target when bound to heparin. This antibody–platelet factor 4–heparin complex is able to activate platelets and may cause venous and arterial thrombosis. Although the immediate discontinuation of heparin is mandatory in this condition, the strategy is insufficient, given the high cumulative risk of thrombosis during 30-day administration of the drug — up to 53 percent without antithrombotic treatment.57 Thus, for patients with suspected or confirmed heparin-induced thrombocytopenia, the use of alternative anticoagulants is recommended.57 The use of DTIs for this condition is theoretically supported by the intense thrombin activity observed in these patients.57-59
Two DTIs, lepirudin and argatroban, are approved in the United States for heparin-induced thrombocytopenia. The data about the efficacy and safety of lepirudin and argatroban come from prospective cohort studies that used historical controls.59-61 In patients with proven heparin-induced thrombocytopenia who were treated with lepirudin, a thrombotic event occurred in approximately 4 percent of patients, as compared with 15 percent in historical controls, but the administration of lepirudin was associated with a higher rate of serious bleeding (14 percent vs. 8 percent).59 Similar results were reported for patients with heparin-induced thrombocytopenia with thromboembolic complications.62 In two series of patients with a clinical diagnosis of heparin-induced thrombocytopenia and thrombosis who were treated with argatroban, the rates of new thrombotic episodes were 13 and 19 percent, as compared with approximately 35 percent in historical controls, with bleeding rates of 6 and 11 percent.60,61
Antihirudin antibodies develop in 40 to 74 percent of patients receiving lepirudin after four days or more of treatment.59,63,64 Of note, fatal anaphylaxis has been described with lepirudin, particularly in patients who are treated again within three months of a previous exposure to this agent.65 In contrast, argatroban does not appear to be immunogenic.66 Thus, lepirudin and argatroban appear to be effective in patients with heparin-induced thrombocytopenia, but drawbacks are an enhanced risk of bleeding and immunogenicity of lepirudin.
Remaining Issues
Direct Thrombin Inhibitors and Liver Function
No available data report about hepatic dysfunction with the use of recombinant hirudins, bivalirudin, or argatroban. The pharmacokinetic and pharmacodynamic properties of ximelagatran and melagatran do not appear to be influenced in the presence of mild-to-moderate impairment of liver function,67 and short-term exposure to ximelagatran (about 12 days) does not appear to increase the risk of hepatotoxicity.68 However, data on longer-term use of ximelagatran and melagatran indicate that alanine aminotransferase levels can become elevated after one to six months in 6 to 10 percent of patients. Although increases that have been reported so far are usually asymptomatic and reversible, even if the medication is continued, the few cases of fatal hepatotoxicity observed with prolonged administration of ximelagatran have led the FDA to deny approval of ximelagatran in the United States,69 and only short-term use of ximelagatran has been approved in Europe.70 The mechanisms of these liver-enzyme abnormalities are still unknown.
Monitoring Activity
The best method to monitor therapy with DTIs has not been clearly established.71-76 The usefulness of the activated partial-thromboplastin time seems limited by its poor linearity and reproducibility, especially when heparin or a vitamin K antagonist is coadministered.71-73,77-79 The ecarin clotting time better reflects the actual plasma concentration of DTIs, but this test is not widely available.74-77,80-82
Recombinant hirudins and argatroban can be monitored with the use of the activated partial-thromboplastin time and bivalirudin with the activated clotting time. In patients with heparin-induced immune thrombocytopenia, antihirudin antibodies form complexes with lepirudin that may reduce the renal clearance of the drug.63 This phenomenon often results in a need to reduce and monitor the dose to maintain the lepirudin anticoagulant effect within the therapeutic range, especially in patients with impaired renal function.57
Since there is no antidote for rapidly reversing the effect of DTIs, monitoring these drugs is important for patients who have a high risk of bleeding. However, given the short half-life of most DTIs, the major anticoagulant effects of DTIs should have disappeared by 12 to 24 hours after the last dose. Preliminary data suggest that recombinant factor VIIa has a limited capacity to reverse the anticoagulant effects of melagatran.83
Conclusions
Despite many well-performed clinical trials, there are few clinical indications for DTIs. For acute coronary syndromes, none of the DTIs have consistently shown superior efficacy combined with a similar safety in comparison with the present standard treatment with heparin and antiplatelet agents. For patients with unstable angina who are undergoing a percutaneous coronary intervention, bivalirudin may be superior to heparin plus GPIIb/IIIa inhibitors administered in case of intraprocedural complications. No DTIs have been convincingly demonstrated to be efficacious and safe for long-term treatment after acute coronary syndromes. In contrast, the efficacy data of ximelagatran in atrial fibrillation are promising, but concern with regard to hepatic toxicity with long-term use must be resolved. When thromboprophylaxis is initiated after serious orthopedic surgery, ximelagatran-containing regimens are less effective than is treatment with low-molecular-weight heparin, but such regimens are superior to warfarin therapy and have a similar safety profile. Preoperative initiation of desirudin is an alternative to the standard approach, but preoperative initiation of melagatran plus ximelagatran increases the risk of bleeding.
Dr. Büller reports having received consulting fees from AstraZeneca.
We are indebted to Dr. Ron J.G. Peters, Department of Cardiology, Academic Medical Center, Amsterdam, for critical review of the manuscript.
Source Information
From the Department of Vascular Medicine, Academic Medical Center, Amsterdam (M.D., S.M., H.R.B.); and the Department of Medicine and Aging, School of Medicine and Aging Research Center, Gabriele D'Annunzio University Foundation, Chieti–Pescara, Italy (M.D.).
Address reprint requests to Dr. Di Nisio at the Academic Medical Center, Department of Vascular Medicine F4-138, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands, or at m.dinisio@amc.uva.nl.
- References
References
1
Tulinsky A . Molecular interactions of thrombin. Semin Thromb Hemost 1996;22:117-124
CrossRef | Web of Science | Medline2
Liaw PCY ,Becker DL ,Stafford AR ,Fredenburgh JC ,Weitz JI . Molecular basis for the susceptibility of fibrin-bound thrombin to inactivation by heparin cofactor II in the presence of dermatan sulfate but not heparin. J Biol Chem 2001;276:20959-20965
CrossRef | Web of Science | Medline3
Weitz JI ,Hudoba M ,Massel D ,Maraganore J ,Hirsh J . Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990;86:385-391
CrossRef | Web of Science | Medline4
Weitz JI ,Leslie B ,Hudoba M . Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. Circulation 1998;97:544-552
Web of Science | Medline5
Bates SM ,Weitz JI . The mechanism of action of thrombin inhibitors. J Invasive Cardiol 2000;12:Suppl F:27F-32F
Medline6
Rydel TJ ,Ravichandran KG ,Tulinsky A , et al. The structure of a complex of recombinant hirudin and human α-thrombin. Science 1990;249:277-280
CrossRef | Web of Science | Medline7
Maraganore JM ,Bourdon P ,Jablonski J ,Ramachandran KL ,Fenton JW II . Design and characterization of Hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 1990;29:7095-7101
CrossRef | Web of Science | Medline8
Parry MA ,Maraganore JM ,Stone SR . Kinetic mechanism for the interaction of Hirulog with thrombin. Biochemistry 1994;33:14807-14814
CrossRef | Web of Science | Medline9
Banner DW ,Hadvary P . Inhibitor binding to thrombin: x-ray crystallographic studies. Adv Exp Med Biol 1993;340:27-33
Web of Science | Medline10
Hauptmann J ,Sturzebecher J . Synthetic inhibitors of thrombin and factor Xa: from bench to bedside. Thromb Res 1999;93:203-241
CrossRef | Web of Science | Medline11
Berry CN ,Girardot C ,Lecoffre C ,Lunven C . Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant hirudin. Thromb Haemost 1994;72:381-386
Web of Science | Medline12
Gustafsson D ,Elg M . The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. Thromb Res 2003;109:Suppl 1:S9-S15
CrossRef | Web of Science | Medline13
Xiao Z ,Theroux P . Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 1998;97:251-256
Web of Science | Medline14
Sarich TC ,Wolzt M ,Eriksson UG , et al. Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects. J Am Coll Cardiol 2003;41:557-564
CrossRef | Web of Science | Medline15
Fischer KG . Hirudin in renal insufficiency. Semin Thromb Hemost 2002;28:467-482
CrossRef | Web of Science | Medline16
Robson R ,White H ,Aylward P ,Frampton C . Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose and gender. Clin Pharmacol Ther 2002;71:433-439
CrossRef | Web of Science | Medline17
Chew DP ,Bhatt DL ,Kimball W , et al. Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials. Am J Cardiol 2003;92:919-923
CrossRef | Web of Science | Medline18
Swan SK ,Hursting MJ . The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000;20:318-329
CrossRef | Web of Science | Medline19
Clarke RJ ,Mayo G ,FitzGerald GA ,Fitzgerald DJ . Combined administration of aspirin and a specific thrombin inhibitor in man. Circulation 1991;83:1510-1518
Web of Science | Medline20
Fager G ,Cullberg M ,Eriksson-Lepkowska M ,Frison L ,Eriksson UG . Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid. Eur J Clin Pharmacol 2003;59:283-289
CrossRef | Web of Science | Medline21
Harrington RA ,Becker RC ,Ezekowitz M , et al. Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:Suppl 3:513S-548S
CrossRef | Web of Science | Medline22
Menon V ,Harrington RA ,Hochman JS , et al. Thrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:Suppl 3:549S-575S
CrossRef | Web of Science | Medline23
The Direct Thrombin Inhibitor Trialists' Collaborative Group
CrossRef | Web of Science | Medline24
White H, Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators
CrossRef | Web of Science | Medline25
Lincoff AM ,Bittl JA ,Harrington RA , et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003;289:853-863[Erratum, JAMA 2003;289:1638.]
CrossRef | Web of Science | Medline26
Wallentin L ,Wilcox RG ,Weaver WD , et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 2003;362:789-797
CrossRef | Web of Science | Medline27
Olsson SB . Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003;362:1691-1698
CrossRef | Web of Science | Medline28
Albers GW ,Diener HC ,Frison L , et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005;293:690-698
CrossRef | Web of Science | Medline29
Antman EM ,Cohen M ,Radley D , et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction: TIMI 11B-ESSENCE meta-analysis. Circulation 1999;100:1602-1608
Web of Science | Medline30
The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators
CrossRef | Web of Science | Medline31
Petersen JL ,Mahaffey KW ,Hasselblad V , et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes: a systematic overview. JAMA 2004;292:89-96
CrossRef | Web of Science | Medline32
Bittl JA ,Strony J ,Brinker JA , et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. N Engl J Med 1995;333:764-769
Full Text | Web of Science | Medline33
Bittl JA ,Chaitman BR ,Feit F ,Kimball W ,Topol EJ . Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 2001;142:952-959
CrossRef | Web of Science | Medline34
Cohen DJ ,Lincoff AM ,Lavelle TA , et al. Economic evaluation of bivalirudin with provisional glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial. J Am Coll Cardiol 2004;44:1792-1800
CrossRef | Web of Science | Medline35
Lincoff AM ,Kleiman NS ,Kereiakes DJ , et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 2004;292:696-703
CrossRef | Web of Science | Medline36
Saw J ,Lincoff AM ,DeSmet W , et al. Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy. J Am Coll Cardiol 2004;44:1194-1199
CrossRef | Web of Science | Medline37
Chew DP ,Lincoff AM ,Gurm H , et al. Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). Am J Cardiol 2005;95:581-585
CrossRef | Web of Science | Medline38
Eikelboom JW ,Anand SS ,Malmberg K ,Weitz JI ,Ginsberg JS ,Yusuf S . Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 2000;355:1936-1942[Erratum, Lancet 2000;356:600.]
CrossRef | Web of Science | Medline39
Singer DE ,Albers GW ,Dalen JE ,Go AS ,Halperin JL ,Manning WJ . Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:Suppl 3:429S-456S
CrossRef | Web of Science | Medline40
LaMonte MP ,Nash ML ,Wang DZ , et al. Argatroban anticoagulation in patients with acute ischemic stroke (ARGIS-1): a randomized, placebo-controlled safety study. Stroke 2004;35:1677-1682
CrossRef | Web of Science | Medline41
Merry AF ,Raudkivi PJ ,Middleton NG , et al. Bivalirudin versus heparin and protamine in off-pump coronary artery bypass surgery. Ann Thorac Surg 2004;77:925-931
CrossRef | Web of Science | Medline42
Geerts WH ,Pineo GF ,Heit JA , et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:Suppl 3:338S-400S
CrossRef | Web of Science | Medline43
Colwell CW Jr ,Berkowitz SD ,Davidson BL , et al. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement: a randomized, double-blind study. J Thromb Haemost 2003;1:2119-2130
CrossRef | Web of Science | Medline44
Francis CW ,Davidson BL ,Berkowitz SD , et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind trial. Ann Intern Med 2002;137:648-655
Web of Science | Medline45
Francis CW ,Berkowitz SD ,Comp PC , et al. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med 2003;349:1703-1712
Full Text | Web of Science | Medline46
Eriksson BI ,Agnelli G ,Cohen AT , et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thromb Haemost 2003;89:288-296
Web of Science | Medline47
Eriksson BI ,Dahl OE ,Buller HR , et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost 2005;3:103-111
CrossRef | Web of Science | Medline48
Eriksson BI ,Agnelli G ,Cohen AT , et al. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost 2003;1:2490-2496
CrossRef | Web of Science | Medline49
Eriksson BI ,Wille-Jorgensen P ,Kalebo P , et al. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N Engl J Med 1997;337:1329-1335
Full Text | Web of Science | Medline50
Eriksson BI ,Ekman S ,Lindbratt S , et al. Prevention of thromboembolism with use of recombinant hirudin: results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement. J Bone Joint Surg Am 1997;79:326-333
Web of Science | Medline51
Fiessinger J-N ,Huisman MV ,Davidson BL , et al. Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial. JAMA 2005;293:681-689
CrossRef | Web of Science | Medline52
Schulman S ,Wahlander K ,Lundstrom T ,Clason SB ,Eriksson H . Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. N Engl J Med 2003;349:1713-1721
Full Text | Web of Science | Medline53
Bergqvist D ,Solhaug J-H ,Holmdahl L , et al. Pharmacokinetics, preliminary efficacy and safety of subcutaneous melagatran and oral ximelagatran: a multicenter study of thromboprophylaxis in elective abdominal surgery. Clin Drug Invest 2004;24:127-136
CrossRef | Web of Science | Medline54
Schiele F ,Lindgaerde F ,Eriksson H , et al. Subcutaneous recombinant hirudin (HBW 023) versus intravenous sodium heparin in treatment of established acute deep vein thrombosis of the legs: a multicentre prospective dose-ranging randomized trial. Thromb Haemost 1997;77:834-838
Web of Science | Medline55
Eriksson H ,Eriksson UG ,Frison L , et al. Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT. Thromb Haemost 1999;81:358-363
Web of Science | Medline56
Buller HR ,Agnelli G ,Hull RD ,Hyers TM ,Prins MH ,Raskob GE . Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:Suppl 3:401S-428S
CrossRef | Web of Science | Medline57
Warkentin TE ,Greinacher A . Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:Suppl 3:311S-337S[Erratum, Chest 2005;127:416.]
CrossRef | Web of Science | Medline58
Boshkov LK ,Warkentin TE ,Hayward CP ,Andrew M ,Kelton JG . Heparin-induced thrombocytopenia and thrombosis: clinical and laboratory studies. Br J Haematol 1993;84:322-328
CrossRef | Web of Science | Medline59
Lubenow N ,Eichler P ,Lietz T ,Farner B ,Greinacher A . Lepirudin for prophylaxis of thrombosis in patients with acute isolated heparin-induced thrombocytopenia: an analysis of 3 prospective studies. Blood 2004;104:3072-3077
CrossRef | Web of Science | Medline60
Lewis BE ,Wallis DE ,Berkowitz SD , et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001;103:1838-1843
Web of Science | Medline61
Lewis BE ,Wallis DE ,Leya F ,Hursting MJ ,Kelton JG . Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch Intern Med 2003;163:1849-1856
CrossRef | Web of Science | Medline62
Greinacher A ,Eichler P ,Lubenow N ,Kwasny H ,Luz M . Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000;96:846-851
Web of Science | Medline63
Eichler P ,Friesen H-J ,Lubenow N ,Jaeger B ,Greinacher A . Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. Blood 2000;96:2373-2378
Web of Science | Medline64
Huhle G ,Hoffmann U ,Song X ,Wang LC ,Heene DL ,Harenberg J . Immunologic response to recombinant hirudin in HIT type II patients during long-term treatment. Br J Haematol 1999;106:195-201
CrossRef | Web of Science | Medline65
Greinacher A ,Lubenow N ,Eichler P . Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation 2003;108:2062-2065
CrossRef | Web of Science | Medline66
Walenga JM ,Ahmad S ,Hoppensteadt D ,Iqbal O ,Hursting MJ ,Lewis BE . Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia. Thromb Res 2002;105:401-405
CrossRef | Web of Science | Medline67
Wahlander K ,Eriksson-Lepkowska M ,Frison L ,Fager G ,Eriksson UG . No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clin Pharmacokinet 2003;42:755-764
CrossRef | Web of Science | Medline68
Food and Drug Administration Cardiovascular and Renal Advisory Committee. Integrated Executive Summary of FDA review for NDA 21-686 Exanta (ximelagatran), September 10, 2004. (Accessed August 11, 2005, at http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4069B1_03_FDA-Backgrounder-Execsummaryredacted.pdf.)
69
AstraZeneca receives action letter from FDA for EXANTA (ximelagatran). Press release from AstraZeneca International, October 11, 2004. (Accessed August 11, 2005, at http://www.astrazeneca.com/pressrelease/3285.aspx.)
70
Successful outcome of the mutual recognition procedure for EXANTA (ximelagatran) in Europe. Press release from AstraZeneca International, May 4, 2004. (Accessed August 11, 2005, at http://www.astrazeneca.com/pressrelease/1898.aspx.)
71
Fenyvesi T ,Jorg I ,Harenberg J . Monitoring of anticoagulant effects of direct thrombin inhibitors. Semin Thromb Hemost 2002;28:361-368
CrossRef | Web of Science | Medline72
Moser M ,Ruef J ,Peter K , et al. Ecarin clotting time but not aPTT correlates with PEG-hirudin plasma activity. J Thromb Thrombolysis 2001;12:165-169
CrossRef | Web of Science | Medline73
Nurmohamed MT ,Berckmans RJ ,Morrien-Salomons WM , et al. Monitoring anticoagulant therapy by activated partial thromboplastin time: hirudin assessment: an evaluation of native blood and plasma assays. Thromb Haemost 1994;72:685-692
Web of Science | Medline74
Callas DD ,Hoppensteadt D ,Iqbal O ,Fareed J . Ecarin clotting time (ECT) is a reliable method for the monitoring of hirudins, argatroban, efegatran and related drugs in therapeutic and cardiovascular indications. Ann Hematol 1996;1:A58-A58 abstract.75
Callas DD ,Fareed J . Comparative anticoagulant effects of various thrombin inhibitors, as determined in the ecarin clotting time method. Thromb Res 1996;83:463-468
CrossRef | Web of Science | Medline76
Radziwon P ,Breddin HK ,Esslinger H-U . Ecarin time is more suitable to monitor PEG-hirudin treatment compared to APTT, TT, ACT, or aIIa-activity. Ann Hematol 1996;1:A57-A57 abstract.77
Walenga JM ,Hoppensteadt D ,Koza M ,Pifarre R ,Fareed J . Comparative studies on various assays for the laboratory evaluation of r-hirudin. Semin Thromb Hemost 1991;17:103-112
CrossRef | Web of Science | Medline78
Marbet GA ,Verstraete M ,Kienast J , et al. Clinical pharmacology of intravenously administered recombinant desulfatohirudin (CGP 39393) in healthy volunteers. J Cardiovasc Pharmacol 1993;22:364-372
CrossRef | Web of Science | Medline79
Schenk JF, Glusa E, Radziwon P, Butti A, Markwardt F, Breddin HK. A recombinant hirudin (IK-HIR02) in healthy volunteers. I. Effects on coagulation parameters and bleeding time. Haemostasis 1996;26:140-9.
80
Casserly IP ,Kereiakes DJ ,Gray WA , et al. Point-of-care ecarin clotting time versus activated clotting time in correlation with bivalirudin concentration. Thromb Res 2004;113:115-121
CrossRef | Web of Science | Medline81
Faaij RA ,van Griensven JMT ,Schoenmaker RC , et al. The effect of warfarin on the pharmacokinetics and pharmacodynamics of napsagatran in healthy male volunteers. Eur J Clin Pharmacol 2001;57:25-29
CrossRef | Web of Science | Medline82
Cho L ,Kottke-Marchant K ,Lincoff AM , et al. Correlation of point-of-care ecarin clotting time versus activated clotting time with bivalirudin concentrations. Am J Cardiol 2003;91:1110-1112
CrossRef | Web of Science | Medline83
Wolzt M ,Levi M ,Sarich TC , et al. Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers. Thromb Haemost 2004;91:1090-1096
Web of Science | Medline
- Citing Articles (128)
Citing Articles
1
Karsten MH Bruins Slot, Eivind Berge, Ritu Saxena, Peter J Koudstaal, Maria I Aguilar, Robert G Hart, Lesly A Pearce, Karsten MH Bruins Slot. 2012. Oral anticoagulants versus antiplatelet therapy for preventing stroke and systemic embolic events in patients with atrial fibrillation. .
CrossRef2
Sarkis Morales-Vidal, Michael J Schneck, Murray Flaster, José Biller. (2012) Direct thrombin inhibitors and factor Xa inhibitors in patients with cerebrovascular disease. Expert Review of Neurotherapeutics 12:2, 179-190
CrossRef3
Yves S. Y. Hsieh, Deni Taleski, Brendan L. Wilkinson, Lakshmi C. Wijeyewickrema, Ty E. Adams, Robert N. Pike, Richard J. Payne. (2012) Effect of O-glycosylation and tyrosine sulfation of leech-derived peptides on binding and inhibitory activity against thrombin. Chemical Communications
CrossRef4
Ji Ji, Jinrui Gan, Jilie Kong, Pengyuan Yang, Baohong Liu, Chang Ji. (2012) Electrochemical detection of the activities of thrombin and its inhibitor. Electrochemistry Communications
CrossRef5
Jeffrey Henry, Song Li. 2011. In Vitro Vascular Tissue Engineering. , 243-256.
CrossRef6
Larisa H Cavallari, Jaekyu Shin, Minoli A Perera. (2011) Role of Pharmacogenomics in the Management of Traditional and Novel Oral Anticoagulants. Pharmacotherapy 31:12, 1192-1207
CrossRef7
Andrea DeDent, Hwan Keun Kim, Dominique Missiakas, Olaf Schneewind. (2011) Exploring Staphylococcus aureus pathways to disease for vaccine development. Seminars in Immunopathology
CrossRef8
Jean-Pierre Bassand. (2011) Current antithrombotic agents for acute coronary syndromes: Focus on bleeding risk. International Journal of Cardiology
CrossRef9
Mohamed Abdel-Wahab, Gert Richardt. (2011) Safety of bivalirudin in patients with coronary artery disease. Expert Opinion on Drug Safety1-10
CrossRef10
Chia-Lun Hsu, Huan-Tsung Chang, Chao-Tsen Chen, Shih-Chun Wei, Yen-Chun Shiang, Chih-Ching Huang. (2011) Highly Efficient Control of Thrombin Activity by Multivalent Nanoparticles. Chemistry - A European Journal 17:39, 10994-11000
CrossRef11
Michael Ganetsky, Kavita M. Babu, Steven D. Salhanick, Robert S. Brown, Edward W. Boyer. (2011) Dabigatran: Review of Pharmacology and Management of Bleeding Complications of This Novel Oral Anticoagulant. Journal of Medical Toxicology
CrossRef12
Dimitris Karnabatidis, Stavros Spiliopoulos, Dimitrios Tsetis, Dimitris Siablis. (2011) Quality Improvement Guidelines for Percutaneous Catheter-Directed Intra-Arterial Thrombolysis and Mechanical Thrombectomy for Acute Lower-Limb Ischemia. CardioVascular and Interventional Radiology
CrossRef13
Sarah A. Spinler, Millie Rajyaguru, Julie K. Atay, John Fanikos. 2011. Parenteral Anticoagulants: Special Considerations in Patients with Chronic Kidney Disease and Obesity. , 241-290.
CrossRef14
Song Li, Jeffrey J.D. Henry. (2011) Nonthrombogenic Approaches to Cardiovascular Bioengineering. Annual Review of Biomedical Engineering 13:1, 451-475
CrossRef15
Maryam Sattari, David T Lowenthal. (2011) Novel Oral Anticoagulants in Development: Dabigatran, Rivaroxaban, and Apixaban. American Journal of Therapeutics 18:4, 332-338
CrossRef16
Alessandro Squizzato, Elena Rancan, Francesco Dentali. (2011) Pharmacotherapy of deep-venous thrombosis: current status and future perspective. Clinical Investigation 1:7, 1039-1047
CrossRef17
Michael D. Ezekowitz, Rangadham Nagarakanti. (2011) Dabigatran in atrial fibrillation: pharmacology and clinical trials. Journal of Interventional Cardiac Electrophysiology
CrossRef18
Stephen D. Bendel, Robert Bona, William L. Baker. (2011) Dabigatran: an oral direct thrombin inhibitor for use in atrial fibrillation. Advances in Therapy 28:6, 460-472
CrossRef19
Pascal Vranckx, Marco Valgimigli, Patrick Serruys. (2011) Looking back into the future: desirudin in acute coronary syndromes and coronary stenting. EuroIntervention 7:2, 263-269
CrossRef20
Meyer Michel Samama. (2011) The mechanism of action of rivaroxaban – an oral, direct Factor Xa inhibitor – compared with other anticoagulants. Thrombosis Research 127:6, 497-504
CrossRef21
Charles S. Craik, Michael J. Page, Edwin L. Madison. (2011) Proteases as therapeutics. Biochemical Journal 435:1, 1-16
CrossRef22
Bernard J. Gersh, Jane E. Freedman, Christopher B. Granger. (2011) Tratamiento antiagregante plaquetario y anticoagulante para la prevención del ictus en pacientes con fibrilación auricular no valvular: nuevos avances basados en la evidencia. Revista Española de Cardiología 64:4, 260-268
CrossRef23
L. Rössig, S. Genth-Zotz, M. Rau, G.R. Heyndrickx, T. Schneider, D.C.L. Gulba, M. Desaga, M. Buerke, S. Harder, A.M. Zeiher. (2011) Argatroban for elective percutaneous coronary intervention: The ARG-E04 multi-center study. International Journal of Cardiology 148:2, 214-219
CrossRef24
Yi-You Chen, Chao-Wei Tseng, Hsin-Yun Chang, Yu-Lun Hung, Chih-Ching Huang. (2011) Gold nanoparticle-based colorimetric assays for coagulation-related proteins and their inhibition reactions. Biosensors and Bioelectronics 26:7, 3160-3166
CrossRef25
Richard C.A. Isaacs, Christina L. Newton, Kellie J. Cutrona, Swati P. Mercer, Bruce D. Dorsey, Colleen M. McDonough, Jacquelynn J. Cook, Julie A. Krueger, S. Dale Lewis, Bobby J. Lucas, Elizabeth A. Lyle, Joseph J. Lynch, Cynthia Miller-Stein, Maria T. Michener, Audrey A. Wallace, Rebecca B. White, Bradley K. Wong. (2011) P3 optimization of functional potency, in vivo efficacy and oral bioavailability in 3-aminopyrazinone thrombin inhibitors bearing non-charged groups at the P1 position. Bioorganic & Medicinal Chemistry Letters 21:5, 1532-1535
CrossRef26
Bernard J. Gersh, Jane E. Freedman, Christopher B. Granger. (2011) Antiplatelet and Anticoagulant Therapy for Stroke Prevention in Patients With Non-valvular Atrial Fibrillation: Evidence Based Strategies and New Developments. Revista Española de Cardiología (English Edition)
CrossRef27
Mariano A Giorgi, Hernán Cohen Arazi, Claudio D Gonzalez, Guillermo Di Girolamo. (2011) Changing anticoagulant paradigms for atrial fibrillation: dabigatran, apixaban and rivaroxaban. Expert Opinion on Pharmacotherapy 12:4, 567-577
CrossRef28
Deborah J. Stearns-Kurosawa, Marcin F. Osuchowski, Catherine Valentine, Shinichiro Kurosawa, Daniel G. Remick. (2011) The Pathogenesis of Sepsis. Annual Review of Pathology: Mechanisms of Disease 6:1, 19-48
CrossRef29
A. V. Mazurov, E. V. Titaeva, S. G. Khaspekova, A. N. Storojilova, V. A. Spiridonova, A. M. Kopylov, A. B. Dobrovolsky. (2011) Characteristics of a New DNA Aptamer, Direct Inhibitor of Thrombin. Bulletin of Experimental Biology and Medicine 150:4, 422-425
CrossRef30
Y. K. Loke, C. S. Kwok. (2011) Dabigatran and rivaroxaban for prevention of venous thromboembolism - systematic review and adjusted indirect comparison. Journal of Clinical Pharmacy and Therapeutics 36:1, 111-124
CrossRef31
Dhara Chaudhari, Rohit Bhuriya, Rohit Arora. (2011) Newer Anticoagulants as an Alternate to Warfarin in Atrial Fibrillation: A Changing Paradigm. American Journal of Therapeutics 18:1, e1-e11
CrossRef32
Steven W Boyce, Dennis F Bandyk, John R Bartholomew, James N Frame, Lawrence Rice. (2011) A Randomized, Open-Label Pilot Study Comparing Desirudin and Argatroban in Patients With Suspected Heparin-Induced Thrombocytopenia With or Without Thrombosis: PREVENT-HIT Study. American Journal of Therapeutics 18:1, 14-22
CrossRef33
Sabrina Touchet, François Carreaux, Bertrand Carboni, Alexandre Bouillon, Jean-Luc Boucher. (2011) Aminoboronic acids and esters: from synthetic challenges to the discovery of unique classes of enzyme inhibitors. Chemical Society Reviews 40:7, 3895
CrossRef34
J. M. Siller-Matula, M. Schwammeis, A. Blann, C. Mannhalter, B. Jilma. (2011) Thrombin as a multi-functional enzyme. Thrombosis and Haemostasis 106:6,
CrossRef35
Catherine J. Lee, Jack E. Ansell. (2011) Direct Thrombin Inhibitors. British Journal of Clinical Pharmacologyno-no
CrossRef36
K. M. Erickson, D. J. Cole. (2010) Carotid artery disease: stenting vs endarterectomy. British Journal of Anaesthesia 105:Supplement 1, i34-i49
CrossRef37
Luke R.E. Bereznicki, Gregory M. Peterson. (2010) REVIEW: New Antithrombotics for Atrial Fibrillation. Cardiovascular Therapeutics 28:5, 278-286
CrossRef38
Jim K. Wong, Ying Tian, Paul Shuttleworth, Anthony D. Caffarelli, Bruce A. Reitz, Christina T. Mora-Mangano. (2010) A Thrombus in the Venous Reservoir While Using Bivalirudin in a Patient with Heparin-Induced Thrombocytopenia Undergoing Heart Transplantation. Anesthesia & Analgesia 111:3, 609-612
CrossRef39
Dimitris Tousoulis, Ioannis Ph. Paroutoglou, Nikolaos Papageorgiou, Marietta Charakida, Christodoulos Stefanadis. (2010) Recent therapeutic approaches to platelet activation in coronary artery disease. Pharmacology & Therapeutics 127:2, 108-120
CrossRef40
Brian P O’Neill, Eric Scot Shaw, Mauricio G Cohen. (2010) Anticoagulation in percutaneous coronary intervention. Interventional Cardiology 2:4, 559-577
CrossRef41
Jeffrey F. Barletta, Brad Cooper, Martin J. Ohlinger. (2010) Adverse drug events associated with disorders of coagulation. Critical Care Medicine 38, S198-S218
CrossRef42
Jerrold H Levy, Marc Azran. (2010) Anesthetic concerns for patients with coagulopathy. Current Opinion in Anaesthesiology 23:3, 400-405
CrossRef43
Birgitta Salmela, Lotta Joutsi-Korhonen, Ellen Saarela, Riitta Lassila. (2010) Comparison of monitoring methods for lepirudin: Impact of warfarin and lupus anticoagulant. Thrombosis Research 125:6, 538-544
CrossRef44
Sidónio C. Freitas, Mário A. Barbosa, M. Cristina L. Martins. (2010) The effect of immobilization of thrombin inhibitors onto self-assembled monolayers on the adsorption and activity of thrombin. Biomaterials 31:14, 3772-3780
CrossRef45
James N. Frame, Lawrence Rice, John R. Bartholomew, Andrew Whelton. (2010) Rationale and design of the PREVENT-HIT study: A randomized, open-label pilot study to compare desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis. Clinical Therapeutics 32:4, 626-636
CrossRef46
Siddhartha Sharma, Dara Singh, Dinesh Kumar, Manjeet Singh, Iftikhar H Wani, Siddhartha Sharma. 2010. Venous thromboembolism prophylaxis for acute spinal cord injury patients. .
CrossRef47
Renato D. Lopes, John H. Alexander, Sana M. Al-Khatib, Jack Ansell, Raphael Diaz, J. Donald Easton, Bernard J. Gersh, Christopher B. Granger, Michael Hanna, John Horowitz, Elaine M. Hylek, John J.V. McMurray, Freek W.A. Verheugt, Lars Wallentin. (2010) Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationale. American Heart Journal 159:3, 331-339
CrossRef48
Bin-Cheng Yin, Min Zhang, Weihong Tan, Bang-Ce Ye. (2010) Peptide-Functionalized Spherical Polyelectrolyte Nanobrushes for Real-Time Sensing of Protease Activity. ChemBioChem 11:4, 494-497
CrossRef49
Taiji Watanabe, Keiichi Kanda, Hatsue Ishibashi-Ueda, Hitoshi Yaku, Yasuhide Nakayama. (2010) Autologous small-caliber âBiotubeâ vascular grafts with argatroban loading: A histomorphological examination after implantation to rabbits. Journal of Biomedical Materials Research Part B: Applied Biomaterials 92B:1, 236-242
CrossRef50
Manfred F. Maitz, Claudia Sperling, Carsten Werner. (2010) Immobilization of the irreversible thrombin inhibitor D-Phe-Pro-Arg-chloromethylketone: A concept for hemocompatible surfaces?. Journal of Biomedical Materials Research Part A 9999A, NA-NA
CrossRef51
Meyer Michel Samama, Grigoris T. Gerotziafas. (2010) Newer anticoagulants in 2009. Journal of Thrombosis and Thrombolysis 29:1, 92-104
CrossRef52
Meijing Wang, Feng Chen, Jian Guan, Jing Zhao, Jiufu Zhang, Renhe Zhao. (2009) Synthesis and Insecticidal Activity of New 4-Hydroxy-2H-1-benzopyran-2-one Derivatives. Applied Biochemistry and Biotechnology 159:3, 768-777
CrossRef53
Alessandro Squizzato, Francesco Dentali, Luigi Steidl, Walter Ageno. (2009) New direct thrombin inhibitors. Internal and Emergency Medicine 4:6, 479-484
CrossRef54
Juan V Llau, Raquel Ferrandis. (2009) New anticoagulants and regional anesthesia. Current Opinion in Anaesthesiology 22:5, 661-666
CrossRef55
Samaha Syed, Robert F. Reilly. (2009) Heparin-induced thrombocytopenia: a renal perspective. Nature Reviews Nephrology 5:9, 501-511
CrossRef56
J.J. Schwartz, J.M. Hatch, Z. Book, N. Lonardo, W.R. Hutson, J.B. Sorensen. (2009) Use of Argatroban during multi-organ procurement: pharmacokinetics and sequelae in recipient of transplanted liver. Clinical Transplantation 23:5, 705-709
CrossRef57
Marc P. Bonaca, Philippe Gabriel Steg, Laurent J. Feldman, John F. Canales, James J. Ferguson, Lars Wallentin, Robert M. Califf, Robert A. Harrington, Robert P. Giugliano. (2009) Antithrombotics in Acute Coronary Syndromes. Journal of the American College of Cardiology 54:11, 969-984
CrossRef58
Anna Lassia Meyer, Doris Malehsa, Christian Kuehn, Christoph Bara, Clemens Gras, Carsten Hafer, Axel Haverich, Martin Strüber. (2009) HeartMate II Implantation in Patients With Heparin-Induced Thrombocytopenia Type II. The Annals of Thoracic Surgery 88:2, 674-675
CrossRef59
Geno Merli, Alex C. Spyropoulos, Joseph A. Caprini. (2009) Use of Emerging Oral Anticoagulants in Clinical Practice. Annals of Surgery 250:2, 219-228
CrossRef60
A. B. Dobrovolsky, E. V. Titaeva, S. G. Khaspekova, V. A. Spiridonova, A. M. Kopylov, A. V. Mazurov. (2009) Inhibition of Thrombin Activity with DNA-Aptamers. Bulletin of Experimental Biology and Medicine 148:1, 33-36
CrossRef61
Massimiliano Cuccioloni, Matteo Mozzicafreddo, Laura Bonfili, Valentina Cecarini, Anna Maria Eleuteri, Mauro Angeletti. (2009) Natural Occurring Polyphenols as Template for Drug Design. Focus on Serine Proteases. Chemical Biology & Drug Design 74:1, 1-15
CrossRef62
Valerie L. Ng. (2009) Anticoagulation Monitoring. Clinics in Laboratory Medicine 29:2, 283-304
CrossRef63
Juan Ignacio Arcelus, Francisco S. Lozano, José L. Ramos, Rafael Alós, Eloy Espín, Pedro Rico, Eduardo Ros. (2009) Prevención de la enfermedad tromboembólica venosa en cirugía general. Cirugía Española 85, 51-61
CrossRef64
Stacy H. James. (2009) Hematology Pharmacology. AACN Advanced Critical Care 20:2, 177-192
CrossRef65
C. W. Khoo, K.-H. Tay, E. Shantsila, G. Y. H. Lip. (2009) Novel oral anticoagulants. International Journal of Clinical Practice 63:4, 630-641
CrossRef66
Matthias Orth. (2009) Factor II- and factor Xa-inhibitors for prevention and treatment of thromboses / Faktor II- und Faktor Xa-Inhibitoren in der Prävention und Therapie von Thrombosen. LaboratoriumsMedizin 33:2, 121-127
CrossRef67
Peter W. Marks. (2009) Coagulation Disorders in the ICU. Clinics in Chest Medicine 30:1, 123-129
CrossRef68
Birgitta Salmela, Anders Albäck, Petri Räike, Mauri Lepäntalo, Riitta Lassila. (2009) A direct thrombin inhibitor, lepirudin, for thrombophilic patients with inoperable critical limb ischemia. Thrombosis Research 123:5, 719-723
CrossRef69
M.D. Jovic, D.G. Nezic, B.M. Calija, D.S. Nenadic, A.M. Knezevic, M.D. Borzanovic, B.M. Krivokapic, I.M. Petrovic, B.P. Djukanovic. (2009) Cardiac surgery in patients with heparin induced thombocytopenia (HIT II). Acta chirurgica iugoslavica 56:1, 47-52
CrossRef70
Javier Granero Xiberta, José María Soler Minoves, Laura Garcia Nuño. (2008) Enfermedad tromboembólica en pacientes de cirugía ortopédica. Medicina Clínica 131, 18-24
CrossRef71
Erika B. Schulze, Benjamin D. Hedley, David Goodale, Carl O. Postenka, Waleed Al-Katib, Alan B. Tuck, Ann F. Chambers, Alison L. Allan. (2008) The thrombin inhibitor Argatroban reduces breast cancer malignancy and metastasis via osteopontin-dependent and osteopontin-independent mechanisms. Breast Cancer Research and Treatment 112:2, 243-254
CrossRef72
Aurangzeb Siddique, Eduard Shantsila, Gregory YH Lip. (2008) The search for new anticoagulants: dabigatran etexilate. Therapy 5:6, 793-796
CrossRef73
Brooke E Baetz, Sarah A Spinler. (2008) Dabigatran Etexilate: An Oral Direct Thrombin Inhibitor for Prophylaxis and Treatment of Thromboembolic Diseases. Pharmacotherapy 28:11, 1354-1373
CrossRef74
Hitoshi Nishio, Masahiro Ieko, Toru Nakabayashi. (2008) New therapeutic option for thromboembolism – dabigatran etexilate. Expert Opinion on Pharmacotherapy 9:14, 2509-2517
CrossRef75
Michael L. Schmitz, Patti Massicotte, Sherry C. Faulkner, Adnan T. Bhutta, Charles E. Johnson, Paul M. Seib, Elizabeth A. Frazier, William P. Fiser, Michiaki Imamura, Robert D. B. Jaquiss. (2008) Management of a Pediatric Patient on the Berlin Heart Excor Ventricular Assist Device With Argatroban After Heparin-Induced Thrombocytopenia. ASAIO Journal 54:5, 546-547
CrossRef76
Teresa Coppola, Michela Varra, Giorgia Oliviero, Aldo Galeone, Giuliana D’Isa, Luciano Mayol, Elena Morelli, Maria-Rosaria Bucci, Valentina Vellecco, Giuseppe Cirino, Nicola Borbone. (2008) Synthesis, structural studies and biological properties of new TBA analogues containing an acyclic nucleotide. Bioorganic & Medicinal Chemistry 16:17, 8244-8253
CrossRef77
Ola E Dahl. (2008) Dabigatran etexilate: an oral direct thrombin inhibitor. Therapy 5:5, 685-695
CrossRef78
Matthew A Cavender, Sunil V Rao, E Magnus Ohman. (2008) Major bleeding: management and risk reduction in acute coronary syndromes. Expert Opinion on Pharmacotherapy 9:11, 1869-1883
CrossRef79
Matthias Hammwöhner, Andreas Goette. (2008) Will Warfarin Soon Be Passé? New Approaches to Stroke Prevention in Atrial Fibrillation. Journal of Cardiovascular Pharmacology 52:1, 18-27
CrossRef80
Nicholas Yacopetti. (2008) Central Venous Catheter-Related Thrombosis. Journal of Infusion Nursing 31:4, 241-248
CrossRef81
Carol M. Lewis, Daniel G. Deschler. (2008) Desirudin Reduces the Rate of Microvenous Thrombosis in a Rat Model. The Laryngoscope 118:7, 1149-1152
CrossRef82
Bengt I. Eriksson, Helen Smith, Uma Yasothan, Peter Kirkpatrick. (2008) Dabigatran etexilate. Nature Reviews Drug Discovery 7:7, 557-558
CrossRef83
Jose A. Hernandez Prada, Sandra L. Madden, David A. Ostrov, Maria A. Hernandez. (2008) Molecular modeling optimization of anticoagulant pyridine derivatives. Journal of Molecular Graphics and Modelling 26:8, 1365-1369
CrossRef84
Robert Siegmund, Klas Boer, Katrin Poeschel, Gunter Wolf, Thomas Deufel, Michael Kiehntopf. (2008) Influence of direct thrombin inhibitor argatroban on coagulation assays in healthy individuals, patients under oral anticoagulation therapy and patients with liver dysfunction. Blood Coagulation & Fibrinolysis 19:4, 288-293
CrossRef85
F.F. van Doormaal, H.R. Büller, S. Middeldorp. (2008) Development in anticoagulant therapy. Critical Reviews in Oncology/Hematology 66:2, 145-154
CrossRef86
Michael T. Ganter, Christoph K. Hofer. (2008) Coagulation Monitoring: Current Techniques and Clinical Use of Viscoelastic Point-of-Care Coagulation Devices. Anesthesia & Analgesia 106:5, 1366-1375
CrossRef87
Y. Kim, Z. Cao, W. Tan. (2008) Molecular assembly for high-performance bivalent nucleic acid inhibitor. Proceedings of the National Academy of Sciences 105:15, 5664-5669
CrossRef88
Gerald Soslau, Aimee Ando, LaToya Floyd, Tom Hong, Lynn Mathew, Yvonne Yen. (2008) Effect of low and high dose melagatran and other antithrombotic drugs on platelet aggregation. Journal of Thrombosis and Thrombolysis 25:2, 198-203
CrossRef89
Sylvia Haas. (2008) New oral Xa and IIa inhibitors: updates on clinical trial results. Journal of Thrombosis and Thrombolysis 25:1, 52-60
CrossRef90
Birgitta Salmela, Arno Nordin, Matti Vuoristo, Heikki Mäkisalo, Kirsti Numminen, Riitta Lassila. (2008) Budd–Chiari syndrome in a young female with factor V Leiden mutation: Successful treatment with lepirudin, a direct thrombin inhibitor. Thrombosis Research 121:6, 769-772
CrossRef91
Robert Siegmund, Klas Boer, Katrin Poeschel, Gunter Wolf, Thomas Deufel, Michael Kiehntopf. (2008) Comparison of the ecarin chromogenic assay and different aPTT assays for the measurement of argatroban concentrations in plasma from healthy individuals and from coagulation factor deficient patients. Thrombosis Research 123:1, 159-165
CrossRef92
Andreas Niedeggen, Justina Lejczyk, Sven Kröner, Christoph Stortz, Sebastian Reith, Uwe Janssens. (2008) Treatment of intracardiac thrombi with argatroban. Acute Cardiac Care 10:4, 221-226
CrossRef93
Y. Blaauw, H. J. G. M. Crijns. (2007) Atrial fibrillation: insights from clinical trials and novel treatment options. Journal of Internal Medicine 262:6, 593-614
CrossRef94
Taro Taketomi, Fania Szlam, Jakob Vinten-Johansen, Jerrold H Levy, Kenichi A Tanaka. (2007) Thrombin-activated thrombelastography for evaluation of thrombin interaction with thrombin inhibitors. Blood Coagulation & Fibrinolysis 18:8, 761-767
CrossRef95
Michael D. Ezekowitz, Paul A. Reilly, Gerhard Nehmiz, Timothy A. Simmers, Rangadham Nagarakanti, Kambiz Parcham-Azad, K. Erik Pedersen, Dominick A. Lionetti, Joachim Stangier, Lars Wallentin. (2007) Dabigatran With or Without Concomitant Aspirin Compared With Warfarin Alone in Patients With Nonvalvular Atrial Fibrillation (PETRO Study). The American Journal of Cardiology 100:9, 1419-1426
CrossRef96
L. Testa, F. Andreotti, G.G.L. Biondi Zoccai, F. Burzotta, F. Bellocci, F. Crea. (2007) Ximelagatran/melagatran against conventional anticoagulation: A meta-analysis based on 22,639 patients. International Journal of Cardiology 122:2, 117-124
CrossRef97
Jerrold H. Levy, Kenichi A. Tanaka, Marcie J. Hursting. (2007) Reducing Thrombotic Complications in the Perioperative Setting: An Update on Heparin-Induced Thrombocytopenia. Anesthesia & Analgesia 105:3, 570-582
CrossRef98
Luca Testa, Ravinai Bhindi, Pierfrancesco Agostoni, Antonio Abbate, Guiseppe GL Biondi Zoccai, William J van Gaal. (2007) The direct thrombin inhibitor ximelagatran/melagatran: a systematic review on clinical applications and an evidence based assessment of risk benefit profile. Expert Opinion on Drug Safety 6:4, 397-406
CrossRef99
W. WIENEN, J.-M. STASSEN, H. PRIEPKE, U. J. RIES, N. HAUEL. (2007) Antithrombotic and anticoagulant effects of the direct thrombin inhibitor dabigatran, and its oral prodrug, dabigatran etexilate, in a rabbit model of venous thrombosis. Journal of Thrombosis and Haemostasis 5:6, 1237-1242
CrossRef100
Martin Beiderlinden, Tanja Treschan, Klaus Görlinger, Jürgen Peters. (2007) Argatroban in Extracorporeal Membrane Oxygenation. Artificial Organs 31:6, 461-465
CrossRef101
Simon J McRae, John W Eikelboom. (2007) Latest medical treatment strategies for venous thromboembolism. Expert Opinion on Pharmacotherapy 8:9, 1221-1233
CrossRef102
Jonathan D. Rich, John M. Maraganore, Edward Young, Rosa-Maria Lidon, Burt Adelman, Paul Bourdon, Supoat Charenkavanich, Jack Hirsh, Pierre Theroux, Christopher P. Cannon. (2007) Heparin resistance in acute coronary syndromes. Journal of Thrombosis and Thrombolysis 23:2, 93-100
CrossRef103
M.-M. Samama, G. Gerotziafas. (2007) Les nouveaux anticoagulants. Annales Pharmaceutiques Françaises 65:2, 85-94
CrossRef104
Natasa Ivanovic, Maarten Beinema, Jacobus RBJ Brouwers, Mark Naunton, Maarten J Postma. (2007) Thromboprophylaxis in total hip-replacement surgery in Europe: acenocoumarol, fondaparinux, dabigatran and rivaroxban. Expert Review of Pharmacoeconomics & Outcomes Research 7:1, 49-58
CrossRef105
Carsten Werner, Manfred F. Maitz, Claudia Sperling. (2007) Current strategies towards hemocompatible coatings. Journal of Materials Chemistry 17:32, 3376
CrossRef106
Sean Burgess, Vesna Zderic, Shahram Vaezy. (2007) Image-guided acoustic hemostasis for hemorrhage in the posterior liver. Ultrasound in Medicine & Biology 33:1, 113-119
CrossRef107
Cheuk-Kit Wong, Harvey D White. (2007) Direct Antithrombins. American Journal of Cardiovascular Drugs 7:4, 249-257
CrossRef108
Matthew L. Ortman, Todd E.H. Hecht. 2007. Prevention of Venous Thromboembolism in the Surgical Patient. , 151-222.
CrossRef109
Patrick Y. Wen, David Schiff, Santosh Kesari, Jan Drappatz, Debra C. Gigas, Lisa Doherty. (2006) Medical management of patients with brain tumors. Journal of Neuro-Oncology 80:3, 313-332
CrossRef110
Christopher S.D. Almond, James Harrington, Ravi Thiagarajan, Christine N. Duncan, Robert LaPierre, David Halwick, Elizabeth D. Blume, Pedro J. del Nido, Ellis J. Neufeld, Francis X. McGowan. (2006) Successful Use of Bivalirudin for Cardiac Transplantation in a Child With Heparin-induced Thrombocytopenia. The Journal of Heart and Lung Transplantation 25:11, 1376-1379
CrossRef111
Chang C Liu, Peter G Schultz. (2006) Recombinant expression of selectively sulfated proteins in Escherichia coli. Nature Biotechnology 24:11, 1436-1440
CrossRef112
Lena M. Napolitano, Theodore E. Warkentin, Amjad AlMahameed, Stanley A. Nasraway. (2006) Heparin-induced thrombocytopenia in the critical care setting: Diagnosis and management^. Critical Care Medicine PAP,
CrossRef113
Gerd Hafner, Dirk Peetz. (2006) Methoden zur Bestimmung von Thrombininhibitoren / Methods for the determination of thrombin inhibitors. LaboratoriumsMedizin 30:5, 296-301
CrossRef114
Andreas Koster, Semi Buz, Roland Hetzer, Hermann Kuppe, Klaus Breddin, Sebastian Harder. (2006) Anticoagulation with argatroban in patients with heparin-induced thrombocytopenia antibodies after cardiovascular surgery with cardiopulmonary bypass: First results from the ARG-E03 trial. The Journal of Thoracic and Cardiovascular Surgery 132:3, 699-700
CrossRef115
A. M. Galan, W. L. van Heerde, G. Escolar, A. Ordinas, J. Sixma, P. G. de Groot. (2006) Antithrombotic action of annexin V proved as efficient as direct inhibition of tissue factor or thrombin. European Journal of Clinical Investigation 36:9, 633-639
CrossRef116
Dagmar Kubitza, Sylvia Haas. (2006) Novel factor Xa inhibitors for prevention and treatment of thromboembolic diseases. Expert Opinion on Investigational Drugs 15:8, 843-855
CrossRef117
Bruce E. Maryanoff, David F. McComsey, Michael J. Costanzo, Stephen C. Yabut, Tianbao Lu, Mark R. Player, Edward C. Giardino, Bruce P. Damiano. (2006) Exploration of Potential Prodrugs of RWJ-445167, an Oxyguanidine-based Dual Inhibitor of Thrombin and Factor Xa. Chemical Biology <html_ent glyph="@amp;" ascii="&"/> Drug Design 68:1, 29-36
CrossRef118
John Jae Young Chang, Chirag R. Parikh. (2006) HEMATOLOGY: ISSUES IN THE DIALYSIS PATIENT: When Heparin Causes Thrombosis: Significance, Recognition, and Management of Heparin-Induced Thrombocytopenia in Dialysis Patients. Seminars in Dialysis 19:4, 297-304
CrossRef119
Samsher Sonawane, Nishaminy Kasbekar, Jeffrey S. Berns. (2006) HEMATOLOGY: ISSUES IN THE DIALYSIS PATIENT: The Safety of Heparins in End-Stage Renal Disease. Seminars in Dialysis 19:4, 305-310
CrossRef120
Robert P. Giugliano, Eugene Braunwald. (2006) The Year in Non–ST-Segment Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology 48:2, 386-395
CrossRef121
Samuel Chackalamannil, Yan Xia. (2006) Thrombin receptor (PAR-1) antagonists as novel antithrombotic agents. Expert Opinion on Therapeutic Patents 16:4, 493-505
CrossRef122
S. Kleinschmidt, B. Stephan, G. Pindur, C. Bauer. (2006) Argatroban. Der Anaesthesist 55:4, 443-450
CrossRef123
Sirak Petros, Thomas Siegemund, Annelie Siegemund, Lothar Engelmann. (2006) The effect of different anticoagulants on thrombin generation. Blood Coagulation & Fibrinolysis 17:2, 131-137
CrossRef124
H. J. M. G. Nelissen-Vrancken. (2006) Directe trombineremmers. MFM 44:3, 83-84
CrossRef125
Y. HUA, R. F. KEEP, K. M. MURASZKO, J. T. HOFF, G. XI. (2006) Reply to more on: the role of thrombin in gliomas. Journal of Thrombosis and Haemostasis 4:1, 287-287
CrossRef126
Eliane Schweizer, Anja Hoffmann-R?der, Jacob A. Olsen, Paul Seiler, Ulrike Obst-Sander, Bj?rn Wagner, Manfred Kansy, David W. Banner, Fran?ois Diederich. (2006) Multipolar interactions in the D pocket of thrombin: large differences between tricyclic imide and lactam inhibitors. Organic & Biomolecular Chemistry 4:12, 2364
CrossRef127
Bengt I Eriksson, Daniel J Quinlan. (2006) Oral Anticoagulants in Development. Drugs 66:11, 1411-1429
CrossRef128
Christopher D. Owens, Mike Belkin. (2005) Thrombosis and Coagulation: Operative Management of the Anticoagulated Patient. Surgical Clinics of North America 85:6, 1179-1189
CrossRef
